MEDISTEP Share Price | Medistep Healthcare Ltd Stock Analysis & Recommendation

Q: How has been the historical performance of Medistep Health.?

Answer:The historical performance of Medistep Health shows significant growth over the past three years, particularly in net sales and profitability.Breakdown:Medistep Health's net sales increased from 7.46 Cr in Mar'23 to 31.62 Cr in Mar'24, and further to 49.65 Cr in Mar'25, indicating a strong upward trend. Total operating income mirrored this growth, rising from 7.46 Cr in Mar'23 to 49.65 Cr in Mar'25. The total expenditure also rose significantly from 6.87 Cr in Mar'23 to 44.06 Cr in Mar'25, reflecting the company's expansion efforts. Operating profit (PBDIT) improved from 0.59 Cr in Mar'23 to 5.59 Cr in Mar'25, while profit before tax rose from 0.55 Cr to 5.54 Cr in the same period. Profit after tax followed suit, increasing from 0.41 Cr in Mar'23 to 4.14 Cr in Mar'25. The company's equity capital grew from 1.07 Cr in Mar'23 to 10.47 Cr in Mar'25, and total liabilities increased from 14.95 Cr to 22.98 Cr. Cash flow from financing activities showed a net inflow of 1.00 Cr in Mar'25, compared to an outflow of 7.00 Cr in Mar'24, indicating improved cash management. Overall, Medistep Health has demonstrated robust growth in sales and profitability, alongside an increase in equity and total assets.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

21.0 k (3,400.00%) Volume

Shareholding (Aug 2025)

FII

0.00%

Held by 0 FIIs

DII

0.00%

Held by 0 DIIs

Promoter

68.96%

How has been the historical performance of Medistep Health.?

13-Nov-2025

Medistep Health has shown significant growth over the past three years, with net sales increasing from 7.46 Cr in Mar'23 to 49.65 Cr in Mar'25, and profit after tax rising from 0.41 Cr to 4.14 Cr. The company has also improved its equity capital and cash flow management during this period.

View full answer

Is Medistep Health. overvalued or undervalued?

14-Nov-2025

As of November 13, 2025, Medistep Health is considered very attractive with a PE ratio of 9.37 and an EV to EBIT ratio of 6.86, significantly lower than its peers, indicating it is undervalued despite a strong recent weekly return of 21.88%.

View full answer

Why is Medistep Healthcare Ltd falling/rising?

19-Jan-2026

As of 18-Jan, the stock price of Medistep Healthcare Ltd is stable at 26.95, with a year-to-date increase of 16.67%. However, declining investor participation and a significant drop in delivery volume may affect future price movements.

View full answer

Which are the latest news on Medistep Health.?

19-Jan-2026

Is Medistep Health. overvalued or undervalued?
How has been the historical performance of Medistep Health.?

Compare Medistep Health. with Similar Stocks

Aro Granite Inds Kshitij Polyline Ganga Bath Fitt.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

Industry

Diversified consumer products

Market cap

INR 38 Cr (Micro Cap)

P/E

9.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.04

Return on Equity

24.59%

Price to Book

2.27

Revenue and Profits:

Net Sales:

11 Cr

(Quarterly Results - Jun 2024)

Net Profit:

1 Cr

Total Returns

Total Returns (Price + Dividend)

Dividend Yield (0%)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-11.91%

6 Months

0.0%

1 Year

0.0%

2 Years

0.0%

3 Years

0.0%

4 Years

0.0%

5 Years

0.0%

Medistep Health. for the last several years.

Risk Adjusted Returns v/s

Returns Beta

Beta has not been calculated since enough price history is not available

News & Corporate Actions

News

Is Medistep Health. overvalued or undervalued?

As of 13 November 2025, the valuation grade for Medistep Health. has moved from does not qualify to very attractive. This indicates a significant improvement in its valuation outlook. The company is currently assessed as undervalued, supported by a PE ratio of 9.37, an EV to EBIT ratio of 6.86, and a robust ROCE of 34.41%. In comparison to its peers, Medistep Health. stands out with a much lower PE ratio than Sun Pharma (36.15) and Divi's Lab (70.4), both of which are categorized as expensive. Additionally, its EV to EBITDA ratio of 6.82 is significantly more favorable than the industry averages, reinforcing its attractive valuation. While Medistep Health. has shown a strong weekly return of 21.88% compared to the Sensex's 1.45%, its longer-term performance metrics remain to be seen....

Read full news article

How has been the historical performance of Medistep Health.?

Answer: The historical performance of Medistep Health shows significant growth over the past three years, particularly in net sales and profitability. Breakdown: Medistep Health's net sales increased from 7.46 Cr in Mar'23 to 31.62 Cr in Mar'24, and further to 49.65 Cr in Mar'25, indicating a strong upward trend. Total operating income mirrored this growth, rising from 7.46 Cr in Mar'23 to 49.65 Cr in Mar'25. The total expenditure also rose significantly from 6.87 Cr in Mar'23 to 44.06 Cr in Mar'25, reflecting the company's expansion efforts. Operating profit (PBDIT) improved from 0.59 Cr in Mar'23 to 5.59 Cr in Mar'25, while profit before tax rose from 0.55 Cr to 5.54 Cr in the same period. Profit after tax followed suit, increasing from 0.41 Cr in Mar'23 to 4.14 Cr in Mar'25. The company's equity capital grew from 1.07 Cr in Mar'23 to 10.47 Cr in Mar'25, and total liabilities increased from 14.95 Cr to 2...

Read full news article

Announcements

No announcement available

Corporate Actions

BOARD MEETING

No Upcoming Board Meetings

DIVIDEND

No Dividend history available

SPLITS

No Splits history available

BONUS

No Bonus history available

RIGHTS

No Rights history available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

323.90%

EBIT Growth (5y)

335.00%

EBIT to Interest (avg)

3.36

Debt to EBITDA (avg)

0.11

Net Debt to Equity (avg)

-0.04

Sales to Capital Employed (avg)

2.23

Tax Ratio

25.09%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

27.88%

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.27

EV to EBIT

6.77

EV to EBITDA

6.73

EV to Capital Employed

2.33

EV to Sales

0.76

PEG Ratio

Dividend Yield

ROCE (Latest)

34.41%

ROE (Latest)

24.59%

Technicals key factors

Indicator

Weekly

Monthly

No records

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Aug 2025

Shareholding Compare (%holding)

Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 0 FIIs

Promoter with highest holding

Prajapati Hetalben Shankarlal (50.08%)

Highest Public shareholder

Nitin Singh Bhati (4.69%)

Individual Investors Holdings

27.29%

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Jun'24 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Jun'24",
        "",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "11.25",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1.39",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "0.02",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "1.02",
          "val2": "NA",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "12.36%",
          "val2": "NA%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2025 is 23.49% vs 33.65% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": " Growth in half year ended Sep 2025 is 20.73% vs 45.56% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "35.07",
          "val2": "28.40",
          "chgp": "23.49%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "3.98",
          "val2": "3.30",
          "chgp": "20.61%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.01",
          "chgp": "-100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "2.97",
          "val2": "2.46",
          "chgp": "20.73%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "11.35%",
          "val2": "11.62%",
          "chgp": "-0.27%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Jun'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Jun'24",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "46.32",
          "val2": "32.50",
          "chgp": "42.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "5.37",
          "val2": "3.69",
          "chgp": "45.53%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.02",
          "val2": "0.04",
          "chgp": "-50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "3.99",
          "val2": "2.71",
          "chgp": "47.23%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "11.59%",
          "val2": "11.35%",
          "chgp": "0.24%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 57.02% vs 323.86% in Mar 2024",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 42.27% vs 609.76% in Mar 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "49.65",
          "val2": "31.62",
          "chgp": "57.02%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "5.59",
          "val2": "3.96",
          "chgp": "41.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.03",
          "val2": "0.05",
          "chgp": "-40.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "4.14",
          "val2": "2.91",
          "chgp": "42.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "11.26%",
          "val2": "12.52%",
          "chgp": "-1.26%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Jun'24 - QoQ

Jun'24

Change(%)

Net Sales

11.25

Operating Profit (PBDIT) excl Other Income

1.39

Interest

0.02

Exceptional Items

0.00

Standalone Net Profit

1.02

Operating Profit Margin (Excl OI)

12.36%

NA%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Quarterly Results

Half Yearly Results Snapshot (Standalone) - Sep'25

Sep'25

Mar'25

Change(%)

Net Sales

35.07

28.40

23.49%

Operating Profit (PBDIT) excl Other Income

3.98

3.30

20.61%

Interest

0.00

0.01

-100.00%

Exceptional Items

0.00

Standalone Net Profit

2.97

2.46

20.73%

Operating Profit Margin (Excl OI)

11.35%

11.62%

-0.27%

Values in Rs Cr.

Compare with Peers

Net Sales

Growth in half year ended Sep 2025 is 23.49% vs 33.65% in Mar 2025

Standalone Net Profit

Growth in half year ended Sep 2025 is 20.73% vs 45.56% in Mar 2025

All Half Yearly Results

Nine Monthly Results Snapshot (Standalone) - Jun'24

Jun'24

Change(%)

Net Sales

46.32

32.50

42.52%

Operating Profit (PBDIT) excl Other Income

5.37

3.69

45.53%

Interest

0.02

0.04

-50.00%

Exceptional Items

0.00

Standalone Net Profit

3.99

2.71

47.23%

Operating Profit Margin (Excl OI)

11.59%

11.35%

0.24%

Values in Rs Cr.

Compare with Peers

Net Sales

Not Applicable: The company has declared_date for only one period

Standalone Net Profit

Not Applicable: The company has declared_date for only one period

All Nine Monthly Results

Annual Results Snapshot (Standalone) - Mar'25

Mar'25

Mar'24

Change(%)

Net Sales

49.65

31.62

57.02%

Operating Profit (PBDIT) excl Other Income

5.59

3.96

41.16%

Interest

0.03

0.05

-40.00%

Exceptional Items

0.00

Standalone Net Profit

4.14

2.91

42.27%

Operating Profit Margin (Excl OI)

11.26%

12.52%

-1.26%

Values in Rs Cr.

Compare with Peers

Net Sales

YoY Growth in year ended Mar 2025 is 57.02% vs 323.86% in Mar 2024

Standalone Net Profit

YoY Growth in year ended Mar 2025 is 42.27% vs 609.76% in Mar 2024

All Annual Results

Company CV

About Medistep Healthcare Ltd

Medistep Healthcare Ltd

Micro Cap

Diversified consumer products

Medistep Healthcare Limited was originally incorporated on June 05, 2023 as a Public Limited Company, pursuant to a Certificate of Incorporation issued by Registrar of Companies, Gujarat. Thereafter, the Company acquired the business of Proprietorship Concern of one of the Promoter Ms. Prajapati Hetalben Girdharilal viz, M/s MG Pharma through the business transfer agreement dated July 02, 2023.

Company Coordinates

No Company Details Available

Medistep Health.

1Day

52 Week

CASH

FII

DII

Promoter

How has been the historical performance of Medistep Health.?

Watch in Real-Time

Is Medistep Health. overvalued or undervalued?

Why is Medistep Healthcare Ltd falling/rising?

Which are the latest news on Medistep Health.?

Compare Medistep Health. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

Returns Beta

News

Is Medistep Health. overvalued or undervalued?

How has been the historical performance of Medistep Health.?

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Aug 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Standalone) - Jun'24 - QoQ

Half Yearly Results Snapshot (Standalone) - Sep'25

Nine Monthly Results Snapshot (Standalone) - Jun'24

Annual Results Snapshot (Standalone) - Mar'25

About Medistep Healthcare Ltd

Company Coordinates